On 19 November 2015, the Committee for Medicinal Products for Human Use (CHMP) recommended the refusal of the marketing authorisation for the medicinal product Solumarv, intended for the treatment of diabetes.
The company that applied for authorisation is Marvel Lifesciences Ltd. It can request a re-examination of the opinion within 15 days of receipt of notification of this negative opinion.
Questions and answers on refusal of the marketing authorisation for Solumarv (insulin human) (PDF/71.87 KB)Adopted
First published: 20/11/2015
Last updated: 20/11/2015
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
Marvel Lifesciences Ltd
|Date of opinion||
|Date of refusal of marketing authorisation||